Latest / Bloomberg Intelligence
Novo Undercuts Lilly’s Obesity Drug Price for Cash-Pay in US
Watch Scarlet and Paul LIVE every day on YouTube: http://bit.ly/3vTiACF.
Bloomberg Intelligence hosted by Paul Sweeney and Scarlet Fu
- Michael Shah, Bloomberg Intelligence Senior Pharma-Biotech Analyst, discusses Novo Nordisk undercutting Eli Lilly & Co. on obesity drugs for cash-pay patients, with introductory doses of Wegovy and Ozempic available for $199 a month. After the first two months, Novo will offer the drugs for $349 a month, 30% less than the current self-pay price, matching Lilly’s price for a low dose of Zepbound.
-- Liana Baker, Bloomberg News Managing Editor for Deals…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.